A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

BACKGROUND: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. METHODS: Patients with Stage II-IV locally advanced or metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Laquente, Berta, Lopez-Martin, Jose, Richards, Donald, Illerhaus, Gerald, Chang, David Z., Kim, George, Stella, Philip, Richel, Dirk, Szcylik, Cezary, Cascinu, Stefano, Frassineti, G. L., Ciuleanu, Tudor, Hurt, Karla, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Von Hoff, Daniel, Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312529/
https://www.ncbi.nlm.nih.gov/pubmed/28202004
http://dx.doi.org/10.1186/s12885-017-3131-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312529/
https://www.ncbi.nlm.nih.gov/pubmed/28202004
http://dx.doi.org/10.1186/s12885-017-3131-x

Ejemplares similares